by Gordon Hensley | Feb 21, 2019 | advocacy, Business, CMS, health care, lobbying, Medicare Cuts, Pharma, U.S. House, U.S. Senate
Among the most complex but significant issues in the unfolding debate about prescription drug pricing reform is pharmacy benefit manager (PBM) rebates — or, so-called “rebates” — as many objective observers see them as kickbacks or opaque...